Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,592.02
(
-0.49%
)
US TECH 100
23,599.80
(
-0.82%
)
Dow Jones
45,939.80
(
-0.62%
)
Brent Oil
104.36
(
-2.09%
)
Bitcoin
69,900.05
(
-1.88%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Shengli post# 100038

Wednesday, 07/28/2010 5:25:47 PM

Wednesday, July 28, 2010 5:25:47 PM

Post# of 257259

Since Interferon HCV treatment is likely to be around for at least a few more years this is another bullet in the ability to predict who will respond.

Understood that IP for use of IL-28B as a diagnostic—which is owned by MRK—has commercial value. What I’m asking is whether ZGEN’s IP for treatment of HCV with IL-28A(,B) has commercial value.

p.s. Welcome to the board!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now